Indeed, analysis of the Genomics of Drug Sensitivity in Cancer database [14] or drug testing in clinical leukemia samples or cell lines revealed a preferential activity of G9a inhibitors in T-ALL compared to other tumor types (Fig. 1B, C and Supplementary Fig. 1D, E) (IC50, BIX01294 mean = 2.52 ± 1.81 μM, 0.63 < x < 6.88; UNC0638 mean = 2.53 ± 1.16 μM, 1.18 < x < 5.03; UNC0642 mean = 3.49 ± 1.54 μM, 1.36 < x < 6.04). Here, EHMT2 is linked to cancer.